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Background: Lung allograft ischemia-reperfusion injury, characterized by 
increased pulmonary vascular esistance, pulmonary edema, and hypoxia, 
is the most frequent cause of early graft failure. Exogenous nitric oxide has 
been shown to reduce lung allograft reperfusion injury. During hypoxia, the 
adenosine triphosphate-sensitive potassium channel is an important ionic 
channel that links the bioenergetic metabolism to membrane xcitability. It 
has been shown to play a critical role in vascular permeability and in 
activation of neutrophils and their subsequent interaction with vessel wall 
cellular components. The purpose of this study was to investigate whether 
nicorandil, a novel nitric oxide generator and adenosine triphosphate- 
sensitive potassium-channel opener, might enhance lung preservation and 
prevent allograft reperfusion injury. Materials and methods: Fourteen dogs 
underwent left lung allotransplantation. Donor lungs were flushed with 
modified Euro-Collins solution and stored for 21 hours at 1 ° C. Immedi- 
ately after transplantation, the contralateral right main pulmonary artery 
and bronchus were ligated to assess isolated allograft function. Hemody- 
namics and arterial blood gas analysis (inspired oxygen fraction 1.0) were 
assessed for 6 hours before the dogs were put to death. After the 
assessment, activity of allograft myeloperoxidase and protein levels of 
bronchoalveolar lavage fluid were measured. Control animals (group I, n = 
5) received no nicorandil. In group II (n = 5), the donor lung received 
nicorandil (24 mg/L) in the flush solution. In addition, recipient animals 
received nicorandil (0.5 mg/kg, intravenously) just before reperfusion, as 
well as a continuous infusion (0.74 - 0.03 mg/kg per hour) during the 
6-hour assessment period. In group I I I  (n = 4), glibenclamide, a selective 
adenosine triphosphate-sensitive potassium-channel blocker, was admin- 
istered 15 minutes before nicorandil administration to both donor and 
recipient. The animals in group I I I  received nicorandil in the same regimen 
as group II. Result: Superior gas exchange and hemodynamics were 
observed in lungs receiving only nicorandil. Allograft myeloperoxidase 
activity and protein levels in bronchoalveolar lavage fluid were significantly 
reduced in group II. Glibenclamide liminated the beneficial effects of 
nicorandil. Conclusions: Nicorandil administration i the flush solution and 
during the reperfusion period ameliorates lung allograft dysfunction, 
improves blood flow, and reduces pulmonary vascular resistance and 
myeloperoxidase activity in the transplanted lung. The present study 
suggests that nicorandil reduces lung allograft reperfusion injury. The 
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beneficial effects of nicorandil may be attributed to its properties as an 
adenosine triphosphate-sensitive potassium-channel opener. (J Thorac 
Cardiovasc Surg 1996;112:1307-14) 
S erious allograft dysfunction occurs in 10% to 20% of clinical lung transplants. 1' 2 It remains an unpre- 
dictable and major clinical problem during the early 
postoperative p riod. Lung allograft reperfusion i jury 
is characterized by poor gas exchange caused by pul- 
monary edema subsequent to increased pulmonary 
vascular esistance (PVR) and pulmonary permeabil- 
ity. A number of strategies relating to preservation 
temperature, 3 state of inflation, 4and administration of
various compounds at the time of harvest or reperfu- 
sion 5-7 have been shown to reduce lung allograft 
dysfunction after prolonged preservation. There is 
evidence that, similar to reperfusion injury in other 
organs, lung allograft reperfusion injury is neutrophil 
mediated. Although free radical-mediated ndothelial 
injury is probable, the mechanism of this neutrophil- 
mediated injury is unclear. 8 
Nicorandil, a nicotinamide nitrate with adenosine 
triphosphate-sensitive potassium (KAxe) channel 
opener activity, 9 has been shown to protect against 
ischemia-reperfusion njury in a variety of experimen- 
tal models and speciesJ °-12 The KAT P channel is 
activated during hypoxiaJ 3 Hypoxia-induced activa- 
tion of the KAa w channel causes membrane hyperpo- 
larization that results in decreased intracellular Ca ++ 
concentration 1~ and maintains cellular ATP. w'13 
Kaxp-channel openers have been shown to have other 
effects, such as suppression of superoxide anion pro- 
duction 12 and tumor necrosis factor-~ productionJ 4 
In addition to its effect on the KAT P channel, nicoran- 
dil, as a nitrate, also acts as a potent nitric oxide 
donor.iS We have shown that exogenous nitric oxide 2' 6 
or nitric oxide donors 5' 16 improve posttransplantation 
function of preserved lung allografts. 
The aim of the present study was to investigate 
whether nicorandil, as a KaTe-channel opener and 
nitric oxide donor, would reduce ischemia-reperfu- 
sion lung injury under conditions imilar to those in 
human lung transplantation. Additionally, we 
sought o determine whether any beneficial effect of 
nicorandil on canine lung allografts was due to a 
Kaxp-channel opener effect or due to the effect of 
nicorandil as a nitric oxide donor. 
Materials and methods 
Fourteen weight-matched pairs of adult mongrel dogs 
were used. All animals received humane care in compli- 
ance with the "Principles of Laboratory Animal Care" 
formulated by the National Society for Medical Research 
and the "Guide for the Care and Use of Laboratory 
Animals" prepared by the National Academy of Sciences 
and published by the National Institutes of Health (NIH 
publication No. 85-23, revised 1985). 
Donor procedure. Harvest and left lung transplantation 
were performed as previously described. 5 In brief, donor 
animals were anesthetized with thiopental sodium given 
intravenously (10 mg/kg) and then by atropine (0.5 nag) 
and were intubated with a 9F endotracheal tube. The 
lungs were ventilated (Bennett MA1; Puritan-Bennett 
Corp., Overland Park, Kan.) with 100% oxygen at a tidal 
volume of 550 ml at a rate of 15 breaths/rain and at a 
positive end-expiratory pressure of 5 cm H20. After a 
median sternotomy, the superior and inferior venae cavae, 
the ascending aorta, the trunks of the pulmonary artery, 
and the trachea were isolated. Animals were given heparin 
(400 U/kg) before insertion of a curved metal-tipped 
cannula (3M Health Care Cardiovascular Systems, Ann 
Arbor, Mich.) through a purse-string suture in the main 
pulmonary artery just distal to the pulmonary valve. 
Before pulmonary artery flush, prostaglandin E 1 (PGE1, 
250 txg) (Prostin VR Pediatric; The Upjohn Company, 
Kalamazoo, Mich.) was injected directly into the pulmo- 
nary artery. Cardiac inflow was occluded by ligation of the 
superior and inferior venae cavae 20 seconds after the 
infusion of PGE 1. The proximal inferior venae cava was 
cut and the left atrial appendage was amputated for 
decompression f the pulmonary artery flush. The lungs 
were perfused immediately, at a pressure of 40 cm H20, 
with 1500 ml of cold (4 ° C) modified Euro-Collins solu- 
tion. During the flush the lungs were cooled topically by 
flooding the thoracic avity with cold (1 ° C) saline solu- 
tion. The flushing pressure was monitored through a 
transducer between the flushing tube and the pulmonary 
artery cannula. When the flushing was completed, the 
trachea was clamped at end-inspiration (tidal volume 550 
ml) and the heart-lung block was excised. The harvested 
organs were stored in modified Euro-Collins solution 
(1 ° C) for 21 hours before implantation. 
Recipient procedure. Left single lung transplantation 
was performed as previously described. 5 Recipient ani- 
mals were anesthetized in the same manner as the donor 
animals and their lungs were ventilated with an adjust- 
able-rate Harvard pump respirator (model 613; Harvard 
Apparatus Co., Inc., South Natik, Mass.) with 98.5% 
oxygen and 1.5% halothane. A femoral arterial line and a 
thermodilution catheter were placed and continuously 
transduced (model 1290A, Hewlett-Packard Company, 
Andover, Mass.). After left pneumonectomy, the con- 
tralateral main pulmonary artery and upper and interme- 
diate bronchi were mobilized and encircled separately. 
The donor left lung was separated from the heart-lung 
block and left single lung allotransplantation was per- 
formed by standard techniques. 5 The allograft was topi- 
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cally cooled with iced slush during implantation. Left 
atrial anastomosis was performed first with a continuous 
everting mattress uture. The pulmonary artery and the 
bronchus were anastomosed by a continuous over-and- 
over suture. After reperfusion of the allograft, a Millar 
pressure transducer (Millar Instruments, Inc., Houston, 
Tex.) was placed in the left atrium and two chest tubes 
were inserted. The contralateral bronchi and pulmonary 
artery were ligated. At this point ventilation was changed 
to 15 breaths/min at a tidal volume of 550 ml and a 
positive end-expiratory pressure of 5 cm H20 (Bennett 
MA1). This ventilator change was required to maintain 
precise levels of inspired oxygen and positive end-expira- 
tory pressure during the subsequent assessment period. 
The chest was closed in layers with absorbable sutures. 
Animals were turned to the supine position for the 6-hour 
assessment period. 
Study groups. In group I (control, n = 5), donor lungs 
were flushed as described earlier and nicorandil was not 
administered. In group II (n = 5), nicorandil (24 mg/L) 
was added to the flush solution described earlier. Recip- 
ients were also given nicorandil (0.5 mg/kg, intravenous 
bolus) immediately before reperfusion and continuously 
(0.74 -+ 0.03 mg/kg per hour) with a syringe pump (model 
355, Orion Research Inc., Boston, Mass.) during the 
6-hour assessment period. In group III (n = 4), donors 
received glibenclamide (a specific KATe-channel blocker) 
(Sigma Chemical Company, St. Louis, Mo.), administered 
at a dose of 3 mg/kg intravenously 15 minutes before 
donor lung flush. For this study glibenclamide was dis- 
solved in dimethyl sulfoxide 2 hours before use. Recipient 
animals in group III also received the same nicorandil 
regimen as group II. Glibenclamide (1.0 mg/kg bolus 
given intravenously) was administered 15 minutes before 
the nicorandil bolus. Group III recipients also received 
intermittent glibenclamide administration (0.5 mg/kg bo- 
lus given intravenously) every 90 minutes during the 
6-hour assessment period (Table I). Corticosteroids were 
not administered to donors or recipients. 
Assessment of lung function. Anesthesia was main- 
tained with intravenous administration f sodium thiopental. 
Cardiac output was measured hourly (model 9520, Baxter 
Healthcare Corporation, Edwards Div., Santa Ana, Calif.). 
Aortic, pulmonary artery, central venous, and left atrial 
pressure were monitored continuously, and arterial and 
mixed venous blood gases were assessed every 15 minutes 
during the 6-hour assessment period. Sodium bicarbonate 
was infused intravenously asnecessary to maintain pH level. 
Intravenous Ringer's lactate solution was administered to
keep central venous pressure within baseline +2 mm Hg. 
After the final measurement, the animals were put to 
death by overdose of sodium thiopental and intravenous 
administration of potassium chloride 20 mEq. Samples of 
transplanted lungs were obtained for tissue myeloperoxi- 
dase (MPO) assay and bronchoalveolar lavage fluid 
(BALF) study. 
BALF analysis. Immediately after death, left lingular 
segments were obtained for use in the BALF study. Fifty 
milliliters of saline solution was injected slowly through 
the lingular bronchus and BALF was collected by gravity. 
This procedure was repeated twice, so that the segment 
was washed with a total of 100 ml saline solution. The 
Table I. Classification of study groups 
Donor Recipient 
Group I 
Group II 
Group III 
No nicorandil No nicorandil 
Nicorandii (24 mg/L) in Nicorandil (0.5 mg/kg) 
flush solution bolus IV + continuous 
0.74 mg/kg per hour 
Glibenclamide (3mg/kg) Glibenclamide (3mg/kg) 
IV + nicorandil (24 IV + nicorandil (0.5 
mg/L) in flush solution mg/kg) bolus IV + 
continuous 0.74 mg/kg 
per hour 
/V, Intravenous. 
BALF was centrifuged at 400g to separate the supernatant 
and cell pellet. One milliliter of the supernatant was 
reserved to measure the concentration of protein by the 
method of Pierce LaboratoriesJ 8 
MPO assay. Recipient lung samples were frozen imme- 
diately by immersion in dichlorodifturomethane (CC12Fa) 
that had been precooled to the freezing point and stored at 
-70°C until assay. Quantitative MPO activity was deter- 
mined as previously described. 8 Frozen lung tissue (100 mg) 
was homogenized in 1 ml of 0.5% hexadecyl-trimethyl- 
ammonium bromide, 5 mmol/L ethylenediaminetetraacetic 
acid, and 50 mmol/L potassium phosphate buffer (pH 6.2) 
with a Broeck tissue grinder (Kontes Glass Co., Vineland, 
N.J.) to release MPO from the primary granules of the 
polymorphonuclear leukocytes. The homogenate was centri- 
fuged at 10,000g for 15 minutes at 4 ° C. The supernatant was 
assayed for MPO activity and total soluble protein by the 
method of Pierce Laboratories. s* Enzyme activity was mea- 
sured spectrophotometrically: 10/xl of tenfold dilute super- 
natant was combined with 0.6 ml Hanks bovine serum 
albumin (0.25% bovine serum albumin added to Hanks 
solution), 0.5 ml of 100 mmol/L potassium phosphate buffer 
(pH 6.2), 0.1 ml 0.05% hydrogen peroxide, and 0.1 ml of 1.25 
mg/ml o-dianisidine. Color development was stopped by 
addition of 0.1 ml of 1% NaN 3 after 5 and 20 minutes at 
room temperature. The optical density was measured at 460 
nm with a spectrophotometer (PMQ II, Carl Zeiss, 
Oberkochen, Germany). The color development from 5 
minutes to 20 minutes was linear. Enzyme activity was 
defined as the amount of MPO that produced an absorbance 
change of 1.0 optical density unit per minute per milligram of 
tissue protein at room temperature (AOD/min/mg). 
Statistical analysis. All data are presented as the 
mean _+ the standard error of the mean. Comparisons 
between groups were made by one-way analysis of vari- 
ance followed by Scheffe's test for multiple comparisons. 
In addition, analysis of variance with repeated measures 
was used to compare an overall difference of hemodynam- 
ics and blood gas data between groups. Differences were 
considered significant when thep value was less than 0.05. 
Results 
There were no significant differences among 
groups with respect to donor weight, recipient 
weight, flushing times and pressure, preservat ion 
time, and warm ischemic t ime (Table II). 
1310 Yamashita et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
November 1996 
600 
,_,  500 
400 
g 
300 
~1 200 
100 
; Group I  = Group l I  --a-- Group l I I  
~ ~  , * p < 0.05 vs Group I 
~" 'J[~'T -~ ' i  _ * , # p < 0.01 vs Group I 
\~xT ~T T 
I gO I I I I I 
0 120 180 240 300 360 
; Group I ° Group II ---a- Group III 
60- 
I T T r 
~1 40 
~" NS 
20 , , , , , , , 
0 60 120 180 240 300 360 
T ime (minutes) 
Fig. 1. Arterial oxygen tension (Pa02) and arterial carbon dioxide tension (Pac02) for groups I, II, and III 
through the 6-hour assessment. There was significant difference in Pao  2 (/9 < 0 .01)  between groups I and 
II, but there were no significant differences in Paco2 among the three groups. NS, Not significant. 
Table II.  Characteristics of experimental groups 
Donor Recipient Flush Flush Storage Warm 
weight weight time pressure time ischemic 
(kg) (kg) (sec) (mmHg) (hour: rain) time (rain) 
Group I (n = 5) 26.9 +_ 0.6 27.8 _+ 0.4 87 -+ 7 18.8 + 1.1 21:07 _+ 4 80 + 4 
Group II (n = 5) 27.1 + 0.8 28.5 -- 0.8 80 _+ 3 17.6 _+ 1.5 20:55 _+ 5 72 _+ 3 
Group I I I  (n = 4) 26.7 + 0.8 27.4 -- 0.9 88 _+ 5 18.5 _+ 0.9 21:01 + 7 75 _+ 5 
Storage time, Period from inflow occ!usion to perfusion; warm ischemic time, period from inflow occlusion to storage in ice + period from implantation to 
reperfusion. 
Gas exchange. Throughout he 6-hour assessment, 
oxygenation i  group II animals was superior to that in 
group I (p < 0.01) (Fig. 1). During the first 45 minutes 
of reperfusion, there was no statistically significant 
difference among the three groups, but gas exchange 
deteriorated rapidly in groups I and III. There were 
significant differences in mean arterial oxygen tension 
after 60 minutes of initial assessment. Arterial oxygen 
tension in groups I, II, and I I I  after 360 minutes of 
assessment were 74 _+ 6, 252 _+ 36 (p < 0.01 vs group 
I), and 162 +_ 68 mm Hg, respectively. Arterial carbon 
dioxide tension was not different among the groups. 
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Fig. 2. Hemodynamic data during the 6-hour assessment. There were no statistical differences in mean 
aortic pressure (AoP) and mean pulmonary pressure among the three groups over time. Cardiac output 
(C.O.) in group II was higher than in groups I and III (p < 0.05) over time. Pulmonary vascular resistance 
(PVR) in group III was higher than in group II (p < 0.05) over time. 
Hemodynamics .  There were no statistically signif- 
icant differences in mean aortic pressure and mean 
pulmonary artery pressure among groups. Cardiac 
output in group II was higher than that in group I (p < 
0.05) after 240 minutes and 360 minutes of assessment, 
respectively, and cardiac output in group II was signif- 
icantly higher than in group III over time (p < 0.05). 
PVR in group III was higher than in group II (p < 
0.05) after 60, 240, and 360 minutes of assessment, and 
PVR in group I was higher than in group II (p < 0.05) 
after 360 minutes of assessment. During the assess- 
ment period PVR in grou p III was significantly higher 
than in group II over time (p < 0.05) (Fig. 2). 
Myeloperoxidase assay. MPO activity in the 
transplanted lungs of group II was significantly 
lower than in groups I and III (groups I, Ii and III: 
0.40 _+ 0.02, 0.30 +_ 0.03, and 0.38 +_ 0.05 AOD/mg 
per minute p < 0.05 vs group I) (Fig. 3). 
BALF protein study. BALF protein levels in 
group II were lower than in the other groups. (levels 
in groups I, II, and III were 5.4 _+ 1.0, 2.2 _+ 0.3 [p < 
0.05], and 5.7 _+ 0.7 mg/ml, respectively) (Fig. 4). 
However, there was no significant difference in total 
amount of BALF among the three groups (700 _+ 
110, 500 _+ 160, and 710 _+ 110 ml, respectively). 
Discuss ion 
Although a large number of strategies have been 
shown to reduce ischemia-reperfusion njury in var- 
ious organs, the exact pathophysiologic mechanisms 
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Fig. 3. Tissue MPO activity after the 6-hour assessment. 
MPO activity in group II was significantly lower than in 
groups I and III (p < 0.05). 
remain unclear. However, it has been demonstrated 
that endothelial dysfunction, ~6' 19 neutrophil activa- 
tion, n'2° oxygen-derived free radicals, '20 platelet 
activation, zzand various cytokines 2~ are involved in 
ischemia-reperfusion injury. Recently the interac- 
tion between endothelium and neutrophil activation 
has been shown to play an important role in lung 
allograft ischemia-reperfusion njury, s' 7 
The KAa-t,-channel is an important ionic channel 
that links cellular bioenergic metabolism to mem- 
brane excitability. 9 KAT e channels are well rePre- 
sented in vascular endothelium, smooth muscle, 
skeletal muscle, endocrine cells, neurons, and cardi- 
omyocytes. 1~These channels are activated by aden- 
osine diphosphate, guanosine diphosphate, and 
acidic intracellular pH. 9 They are blocked by ATP 
and antidiabetic sulfonylureas such as gliben- 
clamide. The adenosine triphosphate/diphosphate 
ratio is thought o be an essential regulatory factor 
for KATp-channels.24 During hypoxia, KAT P chan- 
nels are activated. This activation results in in- 
creased K + conductance or K + efflux, hyperpolar- 
ization of the cellular membrane, with subsequent 
reduction of calcium (Ca ++ ) influx into the cell and 
Ca ++ release from sarcoplasmic reticulum (Table 
!II). 9 Because this massive Ca ++ entry is not com- 
pensated for by Ca ++ elflux during ischemic ondi- 
tions, hypoxia is thought o increase cytosolic free 
2- 
1- 
0 
[] Grou~I [] GroupII 
Protein in BALF  
p < 0.05 
1 
T 
[] Group III 
Fig. 4. Results of BALF protein level after the assess- 
ment period. BALF protein concentration from allograft 
in group II was significantly lower than in group I (p < 
0.05). 
Ca ++ concentration and finally lead to cell death. 9
So that this harmful cascade can be prevented, KATe 
channels are opened during early hypoxia by deple- 
tion of intracellular ATP. This results in a form of 
cellular energy maintenance as evidenced by re- 
duced contractility of cardiomyocytes 12' 15 and vas- 
cular smooth muscle 1°' as and decrease of superox- 
ide anion production in neutrophils. 12
Nicorandil, N-[2-hydroxyethyl] nicotinamide ni- 
trate ester, has been approved for clinical use in 
ischemic heart disease in Japan because it shares the 
pharmacologic properties of nitrates and NAT P- 
channel openers. 25 Several studies in ischemic heart 
models suggested nicorandil had direct and indirect 
myocardial protective ffects. ~2' 26 The present study 
demonstrated that nicorandil improves gas ex- 
change in preserved canine lung allografts. However 
it is not easy to discriminate its beneficial effects as 
a nitric oxide donor and KArp-channel opener. 
KATp-channel openers have various physiologic 
effects derived from increase of K + efflux and 
inhibition of cytosolic free Ca ++ accumulat ions 
The first is an oxygen-sparing effect. 24 Klein and 
associates ~° demonstrated in a pig ischemia-reper- 
fusion study that nicorandil increased coronary 
blood flow like a nitroglycerin; unlike nitroglycerin, 
however, nicorandil increased coronary venous oxy- 
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Table III. Mechanism of KATp-channel opener 
Increased K + permeability 
Hyperpotarization of cell membrane 
Closure of Ca 2+ channels Inhibition of Ca 2+ storage and release 
Reduction of free intracellular Ca 2+ 
gen saturation and substantially decreased regional 
oxygen consumption. 
Second, opening the KATp-channel has a vasodi- 
latory effect and plays a role in the regulation of 
blood flow not only by direct vascular smooth mus- 
cle dilatation but also by endothelial nitric oxide 
synthesis. 11'26'28 Janigro and associates 11 demon- 
strated in their in vitro study that KaTp-channels 
could modify the permeability of the blood-brain 
barrier under pathophysiologic conditions such as 
ischemia. Interestingly, Khimenko, Moore, and Tay- 
lor 29 demonstrated in their isolated perfused rabbit 
model that activation of the NAT P channel could 
protect against and reverse lung endothelial damage 
associated with ischemia-reperfusion injury. In the 
present study, protein levels in BALF, an indicator 
of pulmonary vascular permeability, were signifi- 
cantly lower in the nicorandil group, but there was 
no difference in BALF protein levels between the 
control and glibenclamide groups. 
Finally, KATE-channel openers inhibit superoxide 
anion production by neutrophils 12 and tumor necro- 
sis factor-a production by macrophages. 14 We 3° 
have previously shown in an in vitro model that 
superoxide-induced vascular permeability injury oc- 
curs during the ischemic phase and dimethyl thio- 
urea reduces the permeability damage. 
Although these various KATp-channel effects may 
be important, another potential physiologic mecha- 
nism may explain the beneficial effect of nicorandil. 
Nitric oxide recently has been purported to be an 
important physiologic regulator of the microcircula- 
tion, as well as vascular permeability. 14' 16, 19, 20 Ni- 
tric oxide released from endothelial cells maintains 
vascular homeostatic properties by relaxing vascular 
smooth muscle, 16 inhibiting neutrophil adhesion 31 
and platelet aggregation, 32 and maintaining endo- 
thelial barrier properties. 19 Endogenous, as well as 
exogenous, nitric oxide stimulates guanosine 3'-5'- 
cyclic monophosphorathiate production and regu- 
lates vascular tone. 32 In recent years, a number of 
authors have demonstrated the beneficial effects of 
nitric oxide 2' 14 or nitric oxide donors such as nitro- 
prusside, 7 L-arginine, 17 and nitroglycerin 16 on hu- 
man and canine lung allograft reperfusion injury. 
In the current study, nicorandil ameliorated pul- 
monary ischemia-reperfusion i jury as demon- 
strated by high cardiac output, lower PVR, and 
better gas exchange during the early posttransplan- 
tation period. The allografts in group I I  showed 
significantly lower MPO and BALF protein levels. 
When glibenclamide, a KATp-channel inhibitor, was 
administered simultaneously with nicorandil, the 
beneficial effects of nicorandil were antagonized and 
the glibenclamide group showed no statistically sig- 
nificant difference from the control group. Although 
the nitric oxide donor effect of nicorandil cannot be 
ignored, we believe that the observed improvement 
in lung allograft reperfusion injury after nicorandil 
administration is due to its effect on NAT P channels. 
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Discussion 
Dr. Richard J. Novick (London, Ontario, Canada). 
Concerning the data on oxygenation during reperfusion, I 
believe that the beneficial effects are due to both KAT e - 
channel opening and nitric oxide. At the end of 6 hours of 
reperfusion, the oxygenation is almost the same in group 
II and group III. You have also shown that MPO is 
significantly reduced in group II in the graft, which is not 
primarily due to an effect of KATe-channels. I therefore 
believe that the beneficial results in group II are due to 
both an effect on potassium channels and a nitric oxide 
effect. 
Dr. Yamashita. I think this nicorandil compound has a 
nitric oxide effect, sowe could see a little bit better results 
in group II than group III. This group III was also a little 
bit better than group I. I think this is a nitric oxide effect. 
This time we cannot see any difference between group III 
and group II with regard to arterial oxygen tension, but in 
other parameters we can see a difference. Judging from 
other parameters, I believe the potassium channel opener 
effect will affect these other parameters, including a little 
bit of difference of arterial oxygen tension between group 
II and group III. 
Dr. Joseph M. Areidi (Maywood, Ill.). You continued 
the infusion for a time here. We see that oxygenation does 
continue to decrease over time. Are you investigating 
whether a longer infusion might maintain oxygenation at a 
higher level over time? 
Dr. Yamashita. In our study case we continued the 
nicorandil infusion throughout the 6-hour assessment 
period, but actually I think we do not need to maintain 
continuous infusion for 6 hours. I think infusing this 
compound for 2 hours is enough, but I am not sure 
because I did not examine that point. 
